Sanofi expands R&D in China with €66m Chengdu Hub

By Flora Southey

- Last updated on GMT

Sanofi will support development of polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies through the expansion of its R&D plant in Chengdu, Sichuan province, China.

Sanofi China said it would invest €66m ($77m) in an R&D site to focus on digitalisation and big data analysis of clinical trial data, in Chengdu, Sichuan province. The Chengdu Hub site will manage clinical trial data and files for Sanofi’s pipeline, which targets therapeutic areas including diabetes and cardiovascular diseases, oncology, vaccines, and rare diseases.

According to the French drugmaker, “the Hub will accelerate the availability of trial results, from Phase I to Phase IV…[and] leverage global cutting-edge biological technology for polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies.”

Sanofi plans to employ approximately 300 local R&D experts at the site over the next 18 months.

The Chengdu Hub will join Sanofi’s Asia-Pacific R&D Centre in Shanghai – which opened its doors​ in 2010 – and 11 regional offices across the firm’s growing Chinese network.

China is the ‘third pillar’ of Sanofi’s global clinical sciences and operations, after France and the US, the firm said in a statement​ yesterday.

"Our goal is to link China's innovative achievements with the global ecosystem and develop innovative drugs in China that could benefit patients around the world," ​global head of Sanofi R&D operations Zhang Ji added.

Sanofi did not respond to a request for comment ahead of publication.

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers